Eyegene Inc. (185490)
KRX SM KRX SM Primary Summary
Eyegene Inc. (185490) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Eyegene Inc. ever had a stock split?
Eyegene Inc. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | KRX SM Exchange | - ISIN |
| South Korea Country | 47 Employees | - Last Dividend | 28 Jun 2021 Last Split | - IPO Date |
Overview
EyeGene Inc. is a biopharmaceutical company based in Seoul, South Korea, specializing in the research and development of drugs for the treatment and prevention of age-related diseases. Founded in the year 2000, the company has dedicated over two decades to developing innovative treatments for various health conditions. By focusing on groundbreaking biotechnological approaches, EyeGene Inc. aims to address the medical needs of aging populations through its extensive pipeline of products, ranging from clinical trials to preclinical stages.
Products and Services
- EG-Mirotin:
This drug has completed Phase IIa clinical trial and is designed for the treatment of diabetic retinopathy, a common complication of diabetes that affects the eyes.
- EG-Decorin:
Having completed Phase II clinical trials, EG-Decorin is aimed at treating pressure ulcers and enhancing wound healing, providing solutions for skin integrity issues often seen in immobilized patients.
- EG-Myocin:
This product has finished Phase II clinical trials and targets the treatment of myocardial ischemia/reperfusion injury, a condition that can occur after techniques to restore blood flow to an area of the heart.
- EG-TB:
A preclinical candidate, EG-TB is being developed as a novel vaccine for tuberculosis, aiming to improve upon or complement existing TB vaccination strategies.
- EG-HPV:
This vaccine has completed Phase I clinical trial and is focused on treating cervical cancer caused by human papillomavirus infections.
- EG-Vac:
EG-Vac is being developed for the treatment of immune adjuvant. This product could potentially improve the immune system's response to vaccines or infections.
- EG-COVID:
In phase I clinical trial, EG-COVID represents EyeGene Inc.’s foray into treating the COVID-19 pandemic, showcasing the company's responsiveness to global health emergencies.
- EG-HZ:
Having completed phase I trials, EG-HZ is developed for the treatment of herpes zoster, also known as shingles, a viral disease characterized by a painful skin rash with blisters.
- VitalDB:
This service, vitalDB, is offered as a technological solution for sustaining beautiful vitality, though specific details on its functionality or application are not provided.
